The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy ...

Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...

Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' ...

Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...

Sarfaraz K. Niazi, PhD, gives his opinion on how the recent IQVIA report “Assessing the Biosimilar Void in the US” could be improved for the future.